glp3.wiki

Which GLP-1 Drug Is Best for Weight Loss?

Approval status varies by treatment

Editorially reviewed · Last updated September 8, 2026 · How we review

Key findings

  • There is no single best GLP-1 medicine for everyone. Start with the condition being treated, the approved indication, and individual risks.
  • SURMOUNT-5 favored tirzepatide over semaglutide 1.7/2.4 mg for weight loss at 72 weeks; it did not test every current drug or formulation.
  • Wegovy has cardiovascular risk-reduction evidence in adults with established cardiovascular disease and overweight or obesity. Different cardiovascular trials answer different questions.
  • Oral Wegovy and Foundayo are approved oral options with different dosing, fasting, and interaction instructions.
  • Retatrutide remains investigational. Separate trial averages do not establish superiority or justify delaying needed treatment.

There is no single "best" GLP-1 drug — the right choice depends on your specific health goals, insurance coverage, and whether you need a drug that is available now or can wait for pipeline options. This guide covers every major GLP-1 and incretin-based weight loss drug, from approved medications to next-generation treatments in clinical trials.

Start with your own constraints: the condition being treated, the approved product and formulation, tolerability, and what you can access consistently. Bring those priorities to your clinician. If you already have two drugs in mind, use the comparison directory; for names and formulations, use drug profiles.

Which Drug Is Best for Your Priority?

Best for Maximum Weight Loss

SURMOUNT-5 provides direct evidence favoring tirzepatide over semaglutide 1.7/2.4 mg for average weight loss at 72 weeks in adults with obesity without diabetes. It did not test oral semaglutide or Wegovy HD 7.2 mg.

Retatrutide has reported substantial Phase 3 weight loss, but comparing its trial average with an approved drug does not establish superiority. Do not delay treatment of an existing condition solely to wait for a larger pipeline headline.

Learn more: Retatrutide vs Zepbound | Zepbound vs Wegovy

Best for Proven Cardiovascular Protection

Semaglutide (Wegovy) has a cardiovascular risk-reduction indication supported by SELECT, which found a 20% relative reduction in major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. This is a specific population, not everyone with a risk factor.
SURPASS-CVOT has completed: tirzepatide was noninferior to dulaglutide in people with type 2 diabetes and atherosclerotic cardiovascular disease; superiority for the primary endpoint was not established. Retatrutide's TRIUMPH-Outcomes remains ongoing.
Learn more: Ozempic vs Wegovy | Retatrutide Side Effects

Best Oral Option

Oral Wegovy has a 25 mg maintenance dose in the current label. Take it under the labeled fasting and water instructions. The older 50 mg OASIS 1 study is not the marketed 25 mg regimen.
Orforglipron (Foundayo) was FDA-approved in April 2026 for weight management in eligible adults and can be taken without food or water restrictions. Choice between the oral options still depends on contraindications, drug interactions, tolerability, and access.
Learn more: Retatrutide vs Orforglipron | Oral vs Injection

Best for Diabetes + Weight Loss

Mounjaro and Ozempic are diabetes brands. A clinician should compare glycemic goals, weight goals, other conditions, interactions, and coverage. Superiority in a particular trial does not make one drug best for every person with diabetes.
Learn more: Mounjaro vs Ozempic | Tirzepatide vs Semaglutide

Best for Liver Fat Reduction

The retatrutide Phase 2 liver substudy included 98 participants with baseline liver fat of at least 10%. At 12 mg, relative liver fat reduction was 82.4% at 24 weeks and 86.0% at 48 weeks. MRI-measured fat reduction does not establish MASH resolution, fibrosis improvement, or superiority over another drug.
A Phase 3 multi-agent MASLD master protocol that includes retatrutide (NCT07165028) is currently recruiting.
Learn more: Retatrutide and Fatty Liver | What Is Retatrutide?

Single to triple — how do the classes differ?

Receptor targets describe how medicines work. They do not create a reliable ranking from best to worst: the clinical evidence, approved indication, and patient matter.

Single agonists (GLP-1 only): Semaglutide (Ozempic/Wegovy) targets the GLP-1 receptor to reduce appetite and slow gastric emptying. These were the first generation and remain the most widely prescribed.
Dual agonists (GLP-1 + GIP): Tirzepatide contains both activities. In SURMOUNT-5, it produced 20.2% weight loss versus 13.7% with semaglutide at 72 weeks in adults with obesity without diabetes, at the doses studied.
Triple agonists (GLP-1 + GIP + Glucagon): Retatrutide includes glucagon activity and remains investigational. Glucagon receptor activation is being studied for effects on energy expenditure and hepatic fat metabolism. Preclinical studies support this rationale, but the human trials do not isolate how much weight loss each receptor contributes. Counting receptor targets cannot establish which drug is better.
Combination therapies (Amylin + GLP-1): CagriSema combines two separate drugs targeting amylin and GLP-1 pathways for additive appetite suppression.

How do the five drugs stack up?

Swipe sideways to see every column.

DrugTypeSelected Trial ResultStatusOral Option
Semaglutide (Wegovy/Ozempic)GLP-1-14.9% (STEP 1)FDA approvedYes
Tirzepatide (Zepbound/Mounjaro)GLP-1 + GIP-22.5% (SURMOUNT-1)FDA approvedNo
CagriSemaAmylin + GLP-1-22.7% (REDEFINE 1)NDA filed (2025)No
RetatrutideGLP-1 + GIP + Glucagon-28.7% (TRIUMPH-4)Phase 3No
OrforglipronGLP-1 (oral, non-peptide)-12.4% (ATTAIN-1, efficacy estimand)FDA-approved as Foundayo, April 2026Yes (daily pill)

Can you compare them interactively?

GLP-1 Drug Comparison Tool

Select two or three drugs to view their trial results and approval status. Remove a selected drug before adding another.

Selected trial weight loss

These are average results from separate trials, with different doses, durations and analyses. They do not rank the drugs or predict your weight loss. See the study details below.

RetatrutideTRIUMPH-1, 80 weeks
-28.3%
TirzepatideSURMOUNT-1, 72 weeks
-22.5%
SemaglutideSTEP 1, 68 weeks
-14.9%
FeatureRetatrutideTirzepatideSemaglutide
TypeTripleDualSingle
Brand NamesNot yet namedZepbound, MounjaroWegovy, Ozempic, Rybelsus
ManufacturerEli LillyEli LillyNovo Nordisk
MechanismGLP-1 + GIP + glucagon triple receptor agonistGLP-1 + GIP dual receptor agonistGLP-1 receptor agonist
ReceptorsGLP-1, GIP, GlucagonGLP-1, GIPGLP-1
FDA StatusInvestigationalFDA approvedFDA approved
Selected trial weight loss-28.3% (80 weeks)-22.5% (72 weeks)-14.9% (68 weeks)
Key TrialTRIUMPH-1SURMOUNT-1STEP 1
Study dose12 mg weekly injection (investigational)15 mg weekly injection2.4 mg weekly injection
Study populationAdults with obesity or overweight and a related condition, without diabetesAdults with obesity or overweight and a related condition, without diabetesAdults with obesity or overweight and a related condition, without diabetes
AnalysisEfficacy estimand: assumes continued treatment without prohibited weight-management therapyEfficacy estimand: estimates effects before treatment discontinuationTreatment-policy estimand: includes treatment discontinuation and rescue intervention
ScheduleOnce weekly injection in trialsOnce weekly (injection)Once weekly (injection) or daily (oral), depending on product
Oral OptionNoNoYes
Key considerationInvestigational; no FDA-approved product or dose. SourceApproved weekly injection; the indication depends on the brand. SourceWegovy also has oral and higher-dose injectable options; the selected result is for 2.4 mg injection. Source

Disclaimer: Weight loss results are from separate clinical trials with different populations and cannot be directly compared. Head-to-head trials compare treatments within a defined study population. This tool is for informational purposes only and does not constitute medical advice.

Should you wait for the pipeline triple agonist?

Retatrutide is the first triple agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously. It is being developed by Eli Lilly (the same company behind Mounjaro/Zepbound).
The evidence supports following the program, not treating receptor count or a cross-trial percentage as a reason to replace an approved medicine. Lilly plans a US biologics license application in the first quarter of 2027. That is a filing target, not an FDA approval or launch date.
Learn more: What Is Retatrutide? | Retatrutide Clinical Trials | FDA Approval Timeline

Frequently Asked Questions

Which GLP-1 drug is best for weight loss?

There is no single best option. Tirzepatide produced greater average loss than semaglutide 1.7/2.4 mg in SURMOUNT-5, but that trial did not compare every current formulation. A useful decision also considers approved indication, cardiovascular and other conditions, side effects, preference for a pill or injection, and coverage.

What is the most effective weight loss drug in 2026?

Direct trials are more useful than ranking separate studies. SURMOUNT-5 favored tirzepatide over semaglutide 1.7/2.4 mg. REDEFINE 4 reported greater loss with tirzepatide than CagriSema and did not meet CagriSema’s noninferiority endpoint. Retatrutide remains investigational and has no completed direct comparison establishing superiority.

Is there a GLP-1 weight loss pill?

Yes. Oral Wegovy and Foundayo (orforglipron) are FDA-approved options for eligible adults. They have different dosing, fasting, and interaction instructions; use the label for the prescribed product.

What is a triple agonist?

A triple agonist activates three receptors. Retatrutide targets GLP-1, GIP, and glucagon. That describes its pharmacology, not a guaranteed weight-loss ranking.

How do I choose between Ozempic, Wegovy, Mounjaro, and Zepbound?

Ozempic and Wegovy contain semaglutide; Mounjaro and Zepbound contain tirzepatide. The brands have different approved indications and may have different doses, formulations, and coverage. Start with the condition being treated and the exact product label, then compare expected benefits and risks with your prescriber.

What GLP-1 drugs are coming in 2026-2027?

Foundayo is already approved. CagriSema is under FDA review with a decision expected in late 2026. Lilly plans a US biologics license application in the first quarter of 2027. That is a filing target, not an FDA approval or launch date.

Can you use GLP-1 drugs for weight loss without diabetes?

Yes. Several GLP-1 drugs are FDA-approved specifically for weight loss in adults without diabetes. Wegovy (semaglutide) and Zepbound (tirzepatide) are both approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. You do not need to have type 2 diabetes to be prescribed these medications. Retatrutide is also being studied primarily in non-diabetic obesity populations.

How do GLP-1 drugs work for weight loss?

GLP-1 receptor agonists reduce appetite and food intake and affect gastric emptying and glucose regulation. Tirzepatide also activates GIP; retatrutide activates GIP and glucagon. More targets do not automatically mean more benefit or better safety.

What are the different types of GLP-1 agonists for weight loss?

GLP-1 agonists for weight loss fall into several categories. Single agonists like semaglutide (Wegovy/Ozempic) target only GLP-1. Dual agonists like tirzepatide (Zepbound/Mounjaro) target GLP-1 and GIP. Triple agonists like retatrutide target GLP-1, GIP, and glucagon. Combination therapies like CagriSema pair a GLP-1 agonist with an amylin analog. There are also oral options: oral Wegovy (semaglutide tablets) and approved orforglipron (Foundayo). Each type offers different trade-offs between weight loss efficacy, convenience, and availability.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Semaglutide, tirzepatide and orforglipron have FDA-approved prescription products. Retatrutide and CagriSema remain investigational. Indications and dosing depend on the product.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all guides topics →